home / stock / wint / wint news

WINT News and Press, Windtree Therapeutics Inc. From 02/01/22

Stock Information
Company Name: Windtree Therapeutics Inc.
Stock Symbol: WINT
Market: OTC
Website: windtreetx.com
Menu
WINT WINT Quote WINT Short WINT News WINT Articles WINT Message Board
Get WINT Alerts

News, Short Squeeze, Breakout and More Instantly...
WINT - RIDE, RKLB and CLLS among pre market gainers

AMC Entertainment Holdings (NYSE:AMC) +14% as preliminary Q4 revenue tops consensus. Wallbox (NYSE:WBX) +14% Uber and Wallbox to expand partnership to all of the U.S. Spire Global (NYSE:SPIR) +10% as preliminary Q4 revenue soars 111% Y/Y. ObsEva (NASDAQ:OBSV) +9%. ProQR Th...
WINT - Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

WARRINGTON, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has completed enrollment in its Phase 2 study ...

WINT - Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent

WARRINGTON, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Offic...

WINT - Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Windtree Therapeutics CEO Craig Fraser is a military vet with 30 years experience in biotech, including at Pfizer and J&J. We discuss breaking through the downward spiral of acute heart failure. Economic burden of heart failure near $20B annually and the #1 cause of hospitaliz...
WINT - Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay - Adding to Previously Reported Need for New Pharmacologic Innovation

WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S. hospital claims data analysis...

WINT - Windtree TherapeuticS EPS misses by $0.02

Windtree TherapeuticS (NASDAQ:WINT): Q3 GAAP EPS of -$0.31 misses by $0.02. Press Release. For further details see: Windtree TherapeuticS EPS misses by $0.02

WINT - Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended Sept...
WINT - Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the United States Patent and T...

WINT - CEIX, CEI and RDHL among mid-day movers

Gainers: Camber Energy (NYSE:CEI) +27%. HCW Biologics (NASDAQ:HCWB) +21%. Fuel Tech (NASDAQ:FTEK) +23%. RedHill (NASDAQ:RDHL) +19%. Harmony (NASDAQ:HRMY) +15%. Ginkgo Bioworks (NYSE:DNA) +15%. Arqit Quantum (NASDAQ:ARQQ) +14%. AlloVir (NASDAQ:ALVR) +13%. ViewRay (NASDAQ:VRAY) +13%. Full Truck...

WINT - AlloVir, InflaRx leads healthcare gainers; Galera Therapeutics, Atea Pharmaceuticals among major losers

Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
Previous 10 Next 10